Last reviewed · How we verify
sibutramine, orlistat, diethylpropion
This is a combination of three distinct weight-loss medications that work through different mechanisms: sibutramine inhibits norepinephrine and serotonin reuptake, orlistat inhibits pancreatic lipase to reduce fat absorption, and diethylpropion is a sympathomimetic amine that suppresses appetite.
This is a combination of three distinct weight-loss medications that work through different mechanisms: sibutramine inhibits norepinephrine and serotonin reuptake, orlistat inhibits pancreatic lipase to reduce fat absorption, and diethylpropion is a sympathomimetic amine that suppresses appetite. Used for Obesity management and weight loss.
At a glance
| Generic name | sibutramine, orlistat, diethylpropion |
|---|---|
| Sponsor | Pennington Biomedical Research Center |
| Drug class | Antiobesity agents (combination) |
| Target | Norepinephrine transporter, serotonin transporter, pancreatic lipase, sympathomimetic amine receptor |
| Modality | Small molecule |
| Therapeutic area | Obesity / Weight Management |
| Phase | FDA-approved |
Mechanism of action
Sibutramine acts as a noradrenergic and serotonergic reuptake inhibitor, increasing satiety and thermogenesis. Orlistat works peripherally in the gastrointestinal tract by blocking pancreatic and gastric lipases, preventing dietary fat absorption. Diethylpropion is a sympathomimetic that stimulates the central nervous system to reduce appetite. Together, these agents target weight loss through complementary pathways: central appetite suppression, peripheral fat malabsorption, and metabolic stimulation.
Approved indications
- Obesity management and weight loss
Common side effects
- Dry mouth
- Insomnia
- Headache
- Gastrointestinal disturbances (orlistat-related)
- Increased heart rate
- Hypertension
Key clinical trials
- LOSS- Louisiana Obese Subjects Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: